AKT1 and metabolic dysfunction-associated steatotic liver disease: Taken together, ICV injection of [D-Lys-3]-GHRP-6 ameliorates NAFLD via improving hypothalamic insulin resistance through the PI3K/Akt/mTOR pathway.